02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
10 Nov - 
Adaptimmune Presents Study Designs for Ongoing MAGE-A4 ..
09 Nov - 
NY-ESO Data Presented at the Connective Tissue Oncology..
06 Nov - 
Adaptimmune marks Official Opening of U.K. Headquarters
Related debate
02 Nov - 
Skyldes primært for mange ben i pipeline og forretnings..
02 Nov - 
Den er faldet 12% på få dage
02 Nov - 
Kan ikke få øje på noget nævneværdig fald i GSK ?

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Net Asset Value(s)

17/11/2017 13:20:40
ALLIANCE TRUST PLC                                    At the close of business on Thursday 16 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.8p -       including income, 788.4p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding i..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

17/11/2017 10:28:48
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Alliance Trust PLC : Net Asset Value(s)

16/11/2017 14:31:51
ALLIANCE TRUST PLC                                    At the close of business on Wednesday 15 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 773.4p -       including income, 782.9p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Cuba Ventures Corp. Blockchain Revolupay identifies CCU Coin Cryptocurrency Data mining center in the Bahamas for possible synergy. CEO Steve Marshall meets with CEO of Stonegate Bank USA.
2
ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology
3
Sorenson Holdings, LLC Commences Modified “Dutch Auction” Cash Tender Offer for Senior Unsecured PIK Toggle Notes due 2021
4
Level Brands Announces Closing of $12 Million Initial Public Offering
5
Peak Commercial Sells Two Multi-Family Properties in Prominent San Fernando Valley Neighborhoods for Record-Setting Per Unit Price

Related stock quotes

Glaxosmithkline PLC ORD .. 1,308.00 0.0% Stock price unchanged
GlaxoSmithKline PLC 35.06 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Latest news


Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 November 2017 08:30:12
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171108.1 - EUROWEB1 - 2017-11-18 09:30:12 - 2017-11-18 08:30:12 - 1000 - Website: OKAY